Why undergoing this examination?

Methotrexate (MTX) is a drug used in certain antineoplastic therapies and is also used as an immunosuppressant. It is currently a first generation drug for the treatment of some neoplastic diseases such as acute lymphoblastic leukaemia. In about 20-25% of patients it is necessary to discontinue treatment with MTX due to the side effects they present. It is now known that allelic variants C677T and A1298C in the methylenetetrahydrofolate reductase (MTHFR) gene are associated with an increased risk of toxicity to MTX.

What is this exam?

The Genetic Profile FG – Onco Methotrexate studies the major allelic variants of the MTHFR gene with known clinical relevance, which account for more than 95% of the reduction in enzymatic activity. The aim of the analysis is to identify those patients with a decreased MTHFR enzyme activity and an increased likelihood of developing serious side effects and toxicity to MTX treatment. The result will allow you to adjust the dose or stop the treatment.

For whom is it indicated?

• Patients on pharmacological treatment who wish to customize medication based on their genetic profile
• Patients in whom pharmacological treatments do not show the expected results


Next Generation Sequencing (NGS)


• Guaranteed from the experience of the Synlab group, the absolute European leader in laboratory diagnosis.
• Detailed report including, in addition to the type of metabolism of each enzyme, which drugs can generate toxic effects and adverse reactions, as well as dose recommendations.
• Information provided by the analysis allows the selection of the most appropriate drug, and determines the most appropriate dose for each patient.
• Genetic counseling available at no additional cost, according to the needs of each client.

Extra information

DOCUMENTATION – Available on Extranet for clients:
• Informed Consent
• Clinical Questionnaire
• Fasting is not necessary for the test.

Delivery Time
20 working days
Type of Sample
5 mL whole blood in EDTA tube

Subscribe to our newsletter\n

Subscribe to receive news about our exams